Science
Clinically designed to protect your gut
Postbiotics that help defend against modern stressors — antibiotics, medications, pesticides, stress and poor diet.
Our philosophy
We study how ecosystems evolve.
Microbiome mimicry
We take inspiration from the microbiome’s natural complexity. Rather than focusing on a single organism or compound, our postbiotic approach draws on the broad range of beneficial compounds associated with microbial communities.
Diversity at the center
Our goal is to support the microbial ecosystem already there. We focus on helping protect the gut and its beneficial metabolites from damage caused by the stressors of modern life.
Protects diversity
Clinically studied in humans to help protect and restore gut microbiome diversity.
Supports immune-supporting bacteria
Nourishes keystone microbes, including Akkermansia muciniphila, that help train and regulate immunity.
Broad metabolite payload
Organic acids, short-chain fatty acids, vitamins and bioavailable botanicals in one ferment.
Works alongside probiotics
Designed to enhance the activity of probiotics in finished formulas.
The core technology employs probiotic bacteria to ferment beneficial fibers in a controlled process, yielding heat-inactivated formulations of dead cells, plant substrates, and secondary metabolites (e.g., short-chain fatty acids, bioavailable vitamins, amino acids, neurotransmitters, organic acids, and bacteriocins) that deliver bioactive components supporting a healthy gut microbiome and related systemic functions.
How we make our postbiotics
- >15 Billion total cell count
- High organic acid count
- Optimized metabolite profile
Probiotic species representative of early life microbiome.
Plants that are known functional prebiotics
Published research
Postbiotics during antibiotic treatment
In a single-center, randomized, placebo-controlled pilot trial of 32 patients, researchers studied a fermentation-derived postbiotic alongside antibiotics for non-gastrointestinal infections.
40% higher
Microbiome diversity at the end of antibiotics
The postbiotic group had significantly higher fecal bacterial alpha diversity than the placebo group, measured by the inverse Simpson index. Each group included 16 patients.
Health-associated bacteria enriched
The researchers reported enrichment of health-associated taxa, notably Lachnospiraceae, and reduced Escherichia/Shigella. The treatment was well-tolerated in this trial.
Infection and Immunity
A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxa
Read the published studyAdditional non-public study data is available to qualified partners on request.